Navigation Links
Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
Date:9/16/2008

MARKHAM, ON, Sept. 16 /PRNewswire/ - Cytochroma today announced that it has appointed Steven I. Engel, M.S., Pharm.D., as Vice President, Regulatory Affairs and Quality Assurance. Dr. Engel brings to Cytochroma over 20 years of experience in regulatory affairs and quality assurance, and will be responsible for directing all of Cytochroma's regulatory activities, as well as ensuring that the Company has appropriate quality systems in place. He will be based in Cytochroma's Illinois office.

"Cytochroma's activities in the areas of clinical and regulatory affairs are increasing significantly as we advance three lead product candidates through clinical development," stated Charles W. Bishop, Ph.D., Cytochroma's President and CEO. "For this reason, we have named Dr. Joel Melnick as Vice President, Clinical Research and Development and assigned his former responsibilities in the areas of regulatory affairs and quality assurance to Dr. Steve Engel. Steve has a proven track record of successful new drug registrations and post-marketing support, and we are pleased to have an individual of this caliber helping us secure global regulatory approvals for our products."

Prior to joining Cytochroma, Dr. Engel was Vice President of Regulatory Affairs and Clinical Quality Compliance at Par Pharmaceutical, Inc. where he was responsible for the regulatory strategies of both branded and generic pharmaceutical programs. Prior to joining Par Pharmaceutical, Dr. Engel held regulatory positions at AlgoRx Pharmaceuticals, Vertex Pharmaceuticals, Baxter Healthcare, Abbott Laboratories, Otsuka America Pharmaceuticals, G.D. Searle, and American Cyanamid. He earned his Doctor of Pharmacy degree from the University of Florida, his Master of Science in Pharmacology from the University of North Carolina at Chapel Hill, and his Bachelor's degrees in Pharmacy and Biology from Drake University.

"Cytochroma's portfolio of therapies for chronic kidney disease has tremendous
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
2. Cytochroma Closes $45 Million Series C Financing
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma opens U.S. headquarters in Illinois
5. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
6. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
7. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
8. China Yingxia International, Inc. Appoints New Vice President of Finance
9. SoluBest Appoints Michael Sheckler, MBA, as CEO
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Affitech Appoints Dr. Keith McCullagh as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... In response to its clients’ ... sales, training and consumer engagement challenges, digital ... applications to turn their clients’ visions into reality. ... mobile app creations, are now featured on its ... with Toyota, StudioPMG created a robust cross-platform mobile ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
(Date:9/30/2014)... is available in German . ... several quantum dots in a semiconductor layer. Quantum dots are ... atomic processes. If a short laser pulse is fired at ... quantum dot experiences a change in the electromagnetic field around ... emission of light by the dot. As soon as the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... Pa., Oct. 5 Genaera,Corporation (Nasdaq: GENR ... at two upcoming conferences, Biotech 2007 in Philadelphia ... San Francisco on October,9-11, 2007. Henry R. ... of Genaera, is scheduled to participate in a ...
... BASINGSTOKE, England and CAMBRIDGE, Massachusetts, October 4, Shire ... that Japan,s Ministry of Health, Labour and Welfare ... the treatment of,Hunter syndrome, for sale and marketing ... ELAPRASE is now approved for marketing and commercial,distribution ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into a ... to certain terms and conditions of,the agreement, Horizon will ... its option, Pharmasset may receive a second loan of ... of $10 million by November 30, 2008,provided conditions precedent ...
Cached Biology Technology:Genaera to Present at Biotech 2007 and BIO InvestorForum 2Genaera to Present at Biotech 2007 and BIO InvestorForum 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 4Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... living in densely populated urban areas have a profound impact ... health and fitness of native wildlife. For the first time, ... urbanization and the prevalence and severity of two distinct parasites ... today,s issue of the journal PLOS ONE . ...
... made the world,s temperature records available via Google Earth. ... temperature dataset is one of the most widely used records ... allows users to scroll around the world, zoom in on ... data more easily than ever before. Users can drill ...
... Biological Studies will join Stanford University in leading a ... through a $40 million award by California,s stem cell ... center will bring together experts and investigators from seven ... of genomics the study of the complete genetic ...
Cached Biology News:Presence of humans and urban landscapes increase illness in songbirds, researchers find 2Presence of humans and urban landscapes increase illness in songbirds, researchers find 3World temperature records available via Google Earth 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 3
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Moue Serum 8-12 Weeks Old...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Biology Products: